tradingkey.logo

Travere Therapeutics Inc <TVTX.OQ> expected to post a loss of 56 cents a share - Earnings Preview

ReutersFeb 18, 2025 9:52 PM
  • Travere Therapeutics Inc TVTX.OQ TVTX.O is expected to show a rise in quarterly revenue when it reports results on February 20 for the period ending December 31 2024

  • The San Diego California-based company is expected to report a 62.8% increase in revenue to $73.335 million from $45.06 million a year ago, according to the mean estimate from 15 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Travere Therapeutics Inc is for a loss of 56 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Travere Therapeutics Inc is $31.00​, above​ its last closing price of $22.91. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.69

-0.68

-0.70

Missed

-3

Jun. 30 2024

-0.87

-0.86

-0.91

Missed

-5.7

Mar. 31 2024

-0.97

-0.99

-1.76

Missed

-77.6​

Dec. 31 2023

-1.32

-1.27

-1.03

Beat

19.1

​​Sep. 30 2023

-0.02

-0.14

-1.17

Missed

-719.7

Jun. 30 2023

-1.20

-1.14

-1.13

Beat

1​

Mar. 31 2023

-1.16

-1.17

-1.27

Missed

-8.5

Dec. 31 2022

-1.08

-1.07

-1.03

Beat

4.1

This summary was machine generated February 18 at 21:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI